It can be vital to understand the FGFR3 mutational burden of MIBC, since there are therapeutic agents with clinical benefits for this specific situation.(5) Additionally, patients with FGFR3 alterations tend to have a low likelihood of response to chemotherapy and PD-1 and PD-L1 inhibitors.(5-7) FGFR3 mutations are currently targets for therapeutic agents in bladder cancer. Here, FGFR3 is linked to urinary bladder cancer.